Alzamend Neuro (NASDAQ:ALZN) Trading Up 1.8% – Here’s What Happened

Alzamend Neuro, Inc. (NASDAQ:ALZN)’s stock price was up 1.8% during mid-day trading on Friday . The company traded as high as $1.67 and last traded at $1.66. Approximately 96,748 shares traded hands during mid-day trading, a decline of 83% from the average daily volume of 556,411 shares. The stock had previously closed at $1.63.

Alzamend Neuro Stock Performance

The company has a market capitalization of $13.25 million, a price-to-earnings ratio of -1.68 and a beta of -0.03. The business has a 50 day moving average price of $2.39 and a 200-day moving average price of $4.88.

Alzamend Neuro (NASDAQ:ALZN) last announced its quarterly earnings data on Wednesday, September 11th. The company reported ($1.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.38) by $1.13.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Alzamend Neuro stock. Virtu Financial LLC purchased a new stake in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 26,482 shares of the company’s stock, valued at approximately $26,000. Virtu Financial LLC owned approximately 0.38% of Alzamend Neuro at the end of the most recent reporting period. 49.61% of the stock is owned by institutional investors.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.